| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 2mg | |||
| Other Sizes |
| Targets |
Enalaprilat D5 sodium salt is a labeled form of enalaprilat, which targets angiotensin-converting enzyme (ACE). ACE is a zinc-dependent peptidase that catalyzes the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, and the degradation of bradykinin, a vasodilator. By inhibiting ACE, enalaprilat reduces angiotensin II production and increases bradykinin levels, leading to vasodilation and reduced blood pressure. The deuterium-labeled form has the same biological properties as the unlabeled compound but is used as an analytical standard. Enalaprilat D5 sodium salt is used to study the metabolism and pharmacokinetics of enalaprilat.
|
|---|---|
| ln Vitro |
Enalaprilat D5 sodium salt itself is not evaluated for pharmacological activity, as it is used as an analytical standard. Enalaprilat, the unlabeled compound, is a potent ACE inhibitor with antihypertensive activity. The deuterium-labeled form is used as an internal standard for the quantification of enalaprilat in biological samples by mass spectrometry. Its activity is not characterized in terms of pharmacological effects but rather in terms of analytical properties such as mass spectrometric response and chromatographic behavior. The compound serves as a stable isotope-labeled internal standard for analytical method development.
|
| ln Vivo |
In vivo activity of Enalaprilat D5 sodium salt is not applicable, as the compound is used as an analytical standard rather than as a therapeutic agent. Enalaprilat, the unlabeled compound, is the active metabolite of enalapril and is used clinically for the treatment of hypertension and heart failure. The deuterium-labeled form is not administered therapeutically and is not intended for in vivo studies. Its primary use is as an internal standard for mass spectrometry-based quantification of enalaprilat in biological samples from clinical or preclinical studies.
|
| Enzyme Assay |
In vitro assays for Enalaprilat D5 sodium salt are primarily analytical rather than pharmacological. The compound is used as an internal standard for the quantification of enalaprilat in biological samples by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The deuterium-labeled compound has the same chemical properties as the unlabeled compound but a different mass, allowing it to be distinguished from the endogenous analyte. Analytical methods using Enalaprilat D5 sodium salt involve extraction of enalaprilat from biological samples (plasma, urine), chromatographic separation, and mass spectrometric detection. The compound's purity and stability are characterized to ensure its suitability as an analytical standard.
|
| Cell Assay |
In vitro cellular assays are not applicable for Enalaprilat D5 sodium salt, as the compound is used as an analytical standard rather than for biological activity studies. The compound is not evaluated in cell-based assays for pharmacological activity. Its primary use is in analytical chemistry for the quantification of enalaprilat in biological samples. If cellular assays were to be performed, appropriate cell lines or tissues expressing ACE could be used to assess the biological activity of the unlabeled compound. However, such studies are not typically conducted for deuterium-labeled analytical standards.
|
| Animal Protocol |
In vivo animal studies are not applicable for Enalaprilat D5 sodium salt, as the compound is used as an analytical standard rather than as a therapeutic agent. The deuterium-labeled compound is not administered to animals for efficacy or safety studies. Its primary use is in analytical chemistry for the quantification of enalaprilat in biological samples from clinical or preclinical studies.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Enalaprilat D5 sodium salt are not relevant, as the compound is used as an analytical standard rather than as a therapeutic agent. The compound has a molecular formula of C18H18D5N2NaO5 and a molecular weight of 375.41 g/mol. It is also known as MK-422-d5 sodium. The compound is used as an internal standard for LC-MS/MS analysis of enalaprilat. Its stability and purity are characterized to ensure its suitability for analytical applications. Comprehensive pharmacokinetic parameters are not relevant for an analytical standard.
|
| Toxicity/Toxicokinetics |
Enalaprilat D5 sodium salt is intended for laboratory research use only and has not undergone toxicology testing for therapeutic applications. As a deuterium-labeled analytical standard, the compound is used in small quantities for analytical purposes. Standard handling precautions for chemical research compounds should be followed. Comprehensive toxicological characterization has not been reported, as the compound is not intended for human use. Enalaprilat D5 sodium salt is strictly intended for research purposes as an analytical standard.
|
| Additional Infomation |
Enalaprilat D5 sodium salt is the deuterium-labeled sodium salt form of enalaprilat, the active metabolite of the ACE inhibitor enalapril. It has a molecular formula of C18H18D5N2NaO5 and a molecular weight of 375.41 g/mol. The compound is used as an internal standard for the quantification of enalaprilat in biological samples by mass spectrometry. Enalaprilat D5 sodium salt has not entered clinical trials and is available for research purposes only.
|
| Molecular Formula |
C₁₈H₁₇D₅N₂NA₂O₅
|
|---|---|
| Molecular Weight |
397.39
|
| Exact Mass |
397.163
|
| CAS # |
1356922-29-6
|
| Related CAS # |
Enalaprilat dihydrate;84680-54-6;Enalaprilat-d5;349554-00-3;Enalaprilat;76420-72-9
|
| PubChem CID |
92044428
|
| Appearance |
White to off-white solid powder
|
| LogP |
0.12
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
27
|
| Complexity |
479
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
[2H]C1=C(C(=C(C(=C1[2H])[2H])CC[C@@H](C(=O)[O-])N[C@@H](C)C(=O)N2CCC[C@H]2C(=O)[O-])[2H])[2H].[Na+].[Na+]
|
| InChi Key |
HTOMWWZYNPLIET-CGGLEDJRSA-L
|
| InChi Code |
InChI=1S/C18H24N2O5.2Na/c1-12(16(21)20-11-5-8-15(20)18(24)25)19-14(17(22)23)10-9-13-6-3-2-4-7-13;;/h2-4,6-7,12,14-15,19H,5,8-11H2,1H3,(H,22,23)(H,24,25);;/q;2*+1/p-2/t12-,14-,15-;;/m0../s1/i2D,3D,4D,6D,7D;;
|
| Chemical Name |
disodium;(2S)-1-[(2S)-2-[[(1S)-1-carboxylato-3-(2,3,4,5,6-pentadeuteriophenyl)propyl]amino]propanoyl]pyrrolidine-2-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ≥ 100 mg/mL (~251.64 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5164 mL | 12.5821 mL | 25.1642 mL | |
| 5 mM | 0.5033 mL | 2.5164 mL | 5.0328 mL | |
| 10 mM | 0.2516 mL | 1.2582 mL | 2.5164 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
